IN2015DN00962A - - Google Patents

Download PDF

Info

Publication number
IN2015DN00962A
IN2015DN00962A IN962DEN2015A IN2015DN00962A IN 2015DN00962 A IN2015DN00962 A IN 2015DN00962A IN 962DEN2015 A IN962DEN2015 A IN 962DEN2015A IN 2015DN00962 A IN2015DN00962 A IN 2015DN00962A
Authority
IN
India
Prior art keywords
compound
formula
medicament
description
relates
Prior art date
Application number
Other languages
English (en)
Inventor
Lilli Anselm
David Banner
Wolfgang Haap
Bernd Kuhn
Thomas Luebbers
Jens Uwe Peters
Beat Spinnler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46851300&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2015DN00962(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IN2015DN00962A publication Critical patent/IN2015DN00962A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
IN962DEN2015 2012-08-21 2013-08-19 IN2015DN00962A (en:Method)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12181247 2012-08-21
PCT/EP2013/067218 WO2014029722A1 (en) 2012-08-21 2013-08-19 Novel pyridine derivatives

Publications (1)

Publication Number Publication Date
IN2015DN00962A true IN2015DN00962A (en:Method) 2015-06-12

Family

ID=46851300

Family Applications (1)

Application Number Title Priority Date Filing Date
IN962DEN2015 IN2015DN00962A (en:Method) 2012-08-21 2013-08-19

Country Status (24)

Country Link
US (1) US9409882B2 (en:Method)
EP (1) EP2888244A1 (en:Method)
JP (1) JP2015530997A (en:Method)
KR (1) KR20150044947A (en:Method)
CN (1) CN104583198A (en:Method)
AR (1) AR092172A1 (en:Method)
AU (1) AU2013305102A1 (en:Method)
BR (1) BR112015003217A2 (en:Method)
CA (1) CA2879796A1 (en:Method)
CL (1) CL2015000354A1 (en:Method)
CO (1) CO7200259A2 (en:Method)
CR (1) CR20150073A (en:Method)
EA (1) EA025166B1 (en:Method)
HK (1) HK1206716A1 (en:Method)
IL (1) IL237128A0 (en:Method)
IN (1) IN2015DN00962A (en:Method)
MA (1) MA37893A1 (en:Method)
MX (1) MX2015002026A (en:Method)
PE (1) PE20150995A1 (en:Method)
PH (1) PH12015500262A1 (en:Method)
SG (1) SG11201500900YA (en:Method)
TW (1) TW201412728A (en:Method)
WO (1) WO2014029722A1 (en:Method)
ZA (1) ZA201500625B (en:Method)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY196560A (en) * 2016-02-26 2023-04-19 Hoffmann La Roche Novel Pyrrolidine Derivatives
PT3575284T (pt) 2017-01-24 2021-10-01 Astellas Pharma Inc Composto de prolinamida substituído por fenildifluorometilo

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9903610D0 (sv) 1999-10-06 1999-10-06 Astra Ab Novel compounds II
RU2007129779A (ru) 2005-01-06 2009-02-20 Астразенека Аб (Se) Новые соединения пиридина
BRPI0706725A2 (pt) 2006-01-24 2011-04-05 Actelion Pharmaceuticals Ltda Composto de sais do mesmo , composição farmacêutica , e , uso de um composto
CN104447716A (zh) * 2007-05-09 2015-03-25 沃泰克斯药物股份有限公司 Cftr调节剂
KR20100072098A (ko) 2007-11-30 2010-06-29 에프. 호프만-라 로슈 아게 피리딘 화합물
ES2389042T3 (es) 2008-03-06 2012-10-22 Actelion Pharmaceuticals Ltd. Compuestos de piridina
KR101320790B1 (ko) * 2009-04-20 2013-10-22 에프. 호프만-라 로슈 아게 카텝신 억제제로서의 프롤린 유도체
US8394834B2 (en) * 2009-08-25 2013-03-12 Hoffman-La Roche Inc. Pyrrolidines as NK3 receptor antagonists
EP2760833A1 (en) 2011-09-30 2014-08-06 Endo Pharmaceuticals Inc. Pyridine derivatives

Also Published As

Publication number Publication date
CR20150073A (es) 2015-03-13
IL237128A0 (en) 2015-03-31
AU2013305102A1 (en) 2015-02-12
HK1206716A1 (en) 2016-01-15
WO2014029722A1 (en) 2014-02-27
US9409882B2 (en) 2016-08-09
KR20150044947A (ko) 2015-04-27
CO7200259A2 (es) 2015-02-27
EA025166B1 (ru) 2016-11-30
CN104583198A (zh) 2015-04-29
EA201590363A1 (ru) 2015-06-30
ZA201500625B (en) 2016-08-31
MA37893A1 (fr) 2017-08-31
US20150307472A1 (en) 2015-10-29
PE20150995A1 (es) 2015-06-29
BR112015003217A2 (pt) 2017-07-04
PH12015500262A1 (en) 2015-03-30
SG11201500900YA (en) 2015-03-30
CL2015000354A1 (es) 2015-10-23
AR092172A1 (es) 2015-03-25
TW201412728A (zh) 2014-04-01
MX2015002026A (es) 2015-06-05
CA2879796A1 (en) 2014-02-27
EP2888244A1 (en) 2015-07-01
JP2015530997A (ja) 2015-10-29

Similar Documents

Publication Publication Date Title
PH12016501375A1 (en) Pyridin-2-amides useful as cb2 agonists
PH12015501083B1 (en) Novel pyridine derivatives
MY182328A (en) Pyridine-2-amides useful as cb2 agonists
MY179412A (en) Pyridine-2-amides useful as cb2 agonists
UA118666C2 (uk) Похідні піразолу
JOP20200175A1 (ar) حقنة
PH12015501933B1 (en) Novel pyridine derivatives
IN2014DN06104A (en:Method)
MX349373B (es) Nuevos derivados de pirazina.
IN2015DN01061A (en:Method)
PH12015502471A1 (en) Purine derivatives as cb2 receptor agonists
UA116801C2 (uk) ПОХІДНІ ПІРОЛО[2,3-d]ПІРИМІДИНУ ЯК АГОНІСТИ РЕЦЕПТОРА CB2
MX2014008141A (es) Amidas macrociclicas como inhibidores de proteasas.
IN2014DN10669A (en:Method)
MX346090B (es) Derivados de pirrolidina usados como inhibidores de catepsina.
MX2014008918A (es) Nuevos derivados de pirrolidina.
MX2015016766A (es) Nuevos derivados de tetrazolona.
MY175703A (en) Tablets with improved acceptance and good storage stability
IN2015DN00962A (en:Method)
MX351093B (es) Nuevos derivados de azetidina.
UA80618U (en) Use of n-steroylethanolamine as radiomodifier
UA79010U (ru) Применение n -стеароилэтаноламина в качестве вещества с активным антигриппозным действием